{"id":"daxas","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Depressive disorder","Hepatic failure","Mood swings","Suicidal","Suicidal thoughts","Weight loss"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D"},"_scrapedAt":"2026-03-28T03:11:32.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"COPD Associated with Chronic Bronchitis","diseaseId":"copd-associated-with-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Severe chronic obstructive pulmonary disease","diseaseId":"severe-chronic-obstructive-pulmonary-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02363335","phase":"PHASE1","title":"The Role of Phosphodiesterase Inhibitors in Incretin Secretion","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2015-02-13","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT07393685","phase":"","title":"Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-08-01","conditions":"Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases","enrollment":300},{"nctId":"NCT04069312","phase":"PHASE4","title":"Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-02-11","conditions":"Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis","enrollment":1032},{"nctId":"NCT00246922","phase":"PHASE3","title":"Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12-01","conditions":"Bronchial Asthma","enrollment":150},{"nctId":"NCT00242307","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05-01","conditions":"Bronchial Asthma","enrollment":450},{"nctId":"NCT07263230","phase":"PHASE2","title":"The Safety and Efficacy of Roflumilast Foam in HS","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-04-01","conditions":"Hidradenitis Suppurativa (HS)","enrollment":20},{"nctId":"NCT04636814","phase":"PHASE3","title":"A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-07-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3973},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT07314242","phase":"PHASE2","title":"A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD","status":"NOT_YET_RECRUITING","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2026-01-01","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":120},{"nctId":"NCT07297602","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study","status":"RECRUITING","sponsor":"Nora Mohamed Abdelrazik","startDate":"2025-11-20","conditions":"Atopic Dermatitis","enrollment":36},{"nctId":"NCT07077902","phase":"PHASE2","title":"A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Tulane University","startDate":"2025-09-25","conditions":"Hidradenitis Suppurativa","enrollment":10},{"nctId":"NCT04804605","phase":"PHASE3","title":"Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-02-25","conditions":"Atopic Dermatitis Eczema","enrollment":1220},{"nctId":"NCT05418049","phase":"PHASE2","title":"Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-09-08","conditions":"Fragile X Syndrome","enrollment":45},{"nctId":"NCT04845620","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-04-07","conditions":"Atopic Dermatitis Eczema","enrollment":652},{"nctId":"NCT06998056","phase":"PHASE2","title":"Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2025-06-09","conditions":"Atopic Dermatitis (Eczema)","enrollment":101},{"nctId":"NCT07233291","phase":"PHASE2","title":"A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults","status":"RECRUITING","sponsor":"Ahmed Ibrahim","startDate":"2025-08-20","conditions":"Psoriasis (PsO)","enrollment":36},{"nctId":"NCT07174011","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-01-12","conditions":"Alopecia, Alopecia Areata","enrollment":50},{"nctId":"NCT06631170","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-21","conditions":"Atopic Dermatitis (AD)","enrollment":354},{"nctId":"NCT07105254","phase":"PHASE2","title":"An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)","status":"RECRUITING","sponsor":"Derm Texas, PLLC","startDate":"2025-08-01","conditions":"Non-segmental Vitiligo","enrollment":20},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT05028582","phase":"PHASE3","title":"Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-08-24","conditions":"Scalp Psoriasis","enrollment":432},{"nctId":"NCT04751071","phase":"PHASE1, PHASE2","title":"The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-02-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT06457191","phase":"PHASE1","title":"Roflumilast and TMS Motor Plasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2024-11-06","conditions":"Other Conditions of Brain","enrollment":20},{"nctId":"NCT06648772","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Plaque Psoriasis","enrollment":189},{"nctId":"NCT06860958","phase":"PHASE3","title":"Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-03-01","conditions":"Depressive Disorder, Major","enrollment":60},{"nctId":"NCT05684484","phase":"PHASE4","title":"Role of Roflumilast in Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-02-01","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT04286607","phase":"PHASE3","title":"Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-02-12","conditions":"Chronic Plaque Psoriasis","enrollment":333},{"nctId":"NCT04322929","phase":"PHASE2","title":"Roflumilast in Non-CF Bronchiectasis Study (2019)","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-11-12","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":42},{"nctId":"NCT06677788","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-04-01","conditions":"Non-Alcoholic Steatohepatitis (NASH)","enrollment":55},{"nctId":"NCT06652776","phase":"","title":"The Italian Registry of Patients with Chronic Obstructive Pulmonary Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University of Milan","startDate":"2024-09-30","conditions":"COPD, COPD Exacerbation Acute, Comorbid Chronic Lung Disease on Heart Failure","enrollment":10000},{"nctId":"NCT06643221","phase":"EARLY_PHASE1","title":"Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2018-01-24","conditions":"Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion","enrollment":100},{"nctId":"NCT04773587","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-01-27","conditions":"Atopic Dermatitis Eczema","enrollment":654},{"nctId":"NCT04773600","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-02-24","conditions":"Atopic Dermatitis Eczema","enrollment":683},{"nctId":"NCT05763082","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2023-02-07","conditions":"Plaque Psoriasis","enrollment":414},{"nctId":"NCT05042219","phase":"","title":"Effects of Pulmonary Diseases and Their Treatment on Cardiac Function","status":"RECRUITING","sponsor":"Ayham Daher","startDate":"2022-06-01","conditions":"COPD, Bronchial Asthma, Idiopathic Pulmonary Fibrosis","enrollment":120},{"nctId":"NCT06440473","phase":"PHASE4","title":"Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin","status":"RECRUITING","sponsor":"Rao Dermatology","startDate":"2024-05-28","conditions":"Healthy Skin","enrollment":3},{"nctId":"NCT04973228","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-07-08","conditions":"Seborrheic Dermatitis","enrollment":457},{"nctId":"NCT05796271","phase":"PHASE1","title":"Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01","conditions":"Lymphoma, B-Cell","enrollment":""},{"nctId":"NCT03458546","phase":"PHASE1","title":"Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-05-21","conditions":"Lymphoma, B-Cell","enrollment":14},{"nctId":"NCT04854811","phase":"PHASE2","title":"Roflumilast to Treat Cognitive Sequela After Stroke","status":"COMPLETED","sponsor":"Maastricht University","startDate":"2021-07-07","conditions":"Cerebrovascular Disorders, Memory, Functional Recovery","enrollment":100},{"nctId":"NCT04655313","phase":"PHASE2","title":"Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-11-30","conditions":"Psoriasis, Plaque Psoriasis","enrollment":20},{"nctId":"NCT05369793","phase":"PHASE3","title":"Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-08-01","conditions":"Type 2 Diabetes (Adult Onset), Diabetic Neuropathies","enrollment":60},{"nctId":"NCT05682859","phase":"PHASE4","title":"Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)","status":"RECRUITING","sponsor":"Jacob Pontoppidan Thyssen","startDate":"2023-09-25","conditions":"Chronic Hand Eczema","enrollment":40},{"nctId":"NCT04108377","phase":"PHASE1","title":"Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2019-01-21","conditions":"Asthma","enrollment":5},{"nctId":"NCT03381573","phase":"","title":"Long-term Observational Study of the Safety of Roflumilast","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-12-15","conditions":"COPD","enrollment":135856},{"nctId":"NCT05426915","phase":"","title":"Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.","status":"UNKNOWN","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2023-05-01","conditions":"Copd, COPD Exacerbation","enrollment":750},{"nctId":"NCT04091646","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-04","conditions":"Seborrheic Dermatitis","enrollment":226},{"nctId":"NCT04549870","phase":"PHASE2","title":"Efficacy of Roflumilast in the Treatment of Psoriasis","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2021-01-01","conditions":"Psoriasis","enrollment":46},{"nctId":"NCT05884281","phase":"PHASE1, PHASE2","title":"Efficacy of Roflumilast in Prevention of Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-07","conditions":"Peripheral Neuropathy","enrollment":60},{"nctId":"NCT05278624","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2022-04-15","conditions":"Rosacea","enrollment":40},{"nctId":"NCT05684744","phase":"PHASE2, PHASE3","title":"Roflumilast Versus Methotrexate in Psoriasis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-01-09","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT04746911","phase":"PHASE2","title":"Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-03-01","conditions":"Psoriasis, Plaque Psoriasis","enrollment":10},{"nctId":"NCT03916081","phase":"PHASE2","title":"Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-05-31","conditions":"Atopic Dermatitis","enrollment":136},{"nctId":"NCT04211363","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-20","conditions":"Chronic Plaque Psoriasis","enrollment":439},{"nctId":"NCT04211389","phase":"PHASE3","title":"Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-17","conditions":"Chronic Plaque Psoriasis","enrollment":442},{"nctId":"NCT04128007","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-01-13","conditions":"Plaque Psoriasis","enrollment":304},{"nctId":"NCT03532490","phase":"PHASE2","title":"Trial of Roflumilast in Asthma Management (TRIM)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-08-03","conditions":"Asthma, Obesity","enrollment":38},{"nctId":"NCT03638258","phase":"PHASE2","title":"The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2018-09-21","conditions":"Plaque Psoriasis","enrollment":331},{"nctId":"NCT03764475","phase":"PHASE2","title":"Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2018-12-18","conditions":"Plaque Psoriasis","enrollment":332},{"nctId":"NCT04658654","phase":"PHASE2","title":"Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2021-11-19","conditions":"Mild Cognitive Impairment, Mild Dementia, Amnestic Mild Cognitive Disorder","enrollment":81},{"nctId":"NCT04800172","phase":"PHASE3","title":"The Possible Effects of Roflumilast on Obesity Related Disorders","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-05-01","conditions":"Obesity, PreDiabetes","enrollment":66},{"nctId":"NCT04744090","phase":"PHASE2","title":"Roflumilast as add-on Therapy in Early Cases of ARDS","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-03-21","conditions":"Respiratory Distress Syndrome, Adult","enrollment":76},{"nctId":"NCT04369547","phase":"PHASE1","title":"Roflumilast TMS-EEG Plasticity","status":"WITHDRAWN","sponsor":"University of Calgary","startDate":"2022-01","conditions":"Synaptic Plasticity","enrollment":""},{"nctId":"NCT04755946","phase":"PHASE3","title":"Possible Role of Roflumilast in Diabetic Nephropathy","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2021-03-10","conditions":"Diabetic Nephropathies","enrollment":48},{"nctId":"NCT02743377","phase":"PHASE1, PHASE2","title":"PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2018-04-04","conditions":"Nervous System Disease","enrollment":16},{"nctId":"NCT01973998","phase":"PHASE3","title":"Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization","status":"COMPLETED","sponsor":"Temple University","startDate":"2013-11","conditions":"COPD","enrollment":68},{"nctId":"NCT03988816","phase":"PHASE2","title":"Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2019-12-06","conditions":"Bronchiectasis Adult","enrollment":30},{"nctId":"NCT01433666","phase":"PHASE2","title":"Roflumilast and Cognition","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-09","conditions":"Dementia","enrollment":22},{"nctId":"NCT01509677","phase":"PHASE3","title":"Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-02-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT04122547","phase":"PHASE3","title":"Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2015-01","conditions":"Exacerbation Copd, Bronchiectasis, Lung Function Decreased","enrollment":40},{"nctId":"NCT04090294","phase":"EARLY_PHASE1","title":"Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-10-01","conditions":"Bronchiectasis","enrollment":35},{"nctId":"NCT03428334","phase":"PHASE2","title":"Roflumilast in Non-CF Bronchiectasis Study","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2018-05-10","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":20},{"nctId":"NCT02671942","phase":"PHASE2","title":"A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2016-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":55},{"nctId":"NCT01630200","phase":"PHASE4","title":"Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease and Allied Conditions","enrollment":80},{"nctId":"NCT01862029","phase":"PHASE1, PHASE2","title":"Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-05-22","conditions":"Obesity","enrollment":24},{"nctId":"NCT02340520","phase":"PHASE3","title":"Enhancement of Corticosteroid Efficacy in COPD","status":"COMPLETED","sponsor":"UConn Health","startDate":"2014-12","conditions":"COPD","enrollment":13},{"nctId":"NCT02451540","phase":"PHASE2","title":"Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging","status":"TERMINATED","sponsor":"FLUIDDA nv","startDate":"2015-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":13},{"nctId":"NCT02097992","phase":"PHASE1, PHASE2","title":"Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD","status":"COMPLETED","sponsor":"University of Miami","startDate":"2013-02","conditions":"COPD","enrollment":11},{"nctId":"NCT01745848","phase":"PHASE4","title":"Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":26},{"nctId":"NCT03073798","phase":"PHASE4","title":"The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2013-03-18","conditions":"COPD, Chronic Bronchitis, Emphysema","enrollment":12},{"nctId":"NCT02015767","phase":"","title":"Patient Registry of Roflumilast In Real Life","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1950},{"nctId":"NCT02068456","phase":"","title":"Post Marketing Surveillance of Roflumilast in Korea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09-18","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1837},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01443845","phase":"PHASE4","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-30","conditions":"COPD, COPD Exacerbation, Lung Diseases","enrollment":2354},{"nctId":"NCT01730404","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-10","conditions":"COPD","enrollment":55},{"nctId":"NCT01888952","phase":"EARLY_PHASE1","title":"Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)","status":"COMPLETED","sponsor":"Anand B. Karnad","startDate":"2013-07","conditions":"Advanced B-cell Lymphoid Malignancies","enrollment":10},{"nctId":"NCT01473758","phase":"PHASE2","title":"Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-02","conditions":"Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation","enrollment":81},{"nctId":"NCT01313494","phase":"PHASE3","title":"A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"COPD","enrollment":626},{"nctId":"NCT01856764","phase":"PHASE2","title":"Topical Roflumilast in Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-06","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT01765192","phase":"PHASE2","title":"Roflumilast Plus Montelukast in Adults With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Asthma","enrollment":64},{"nctId":"NCT02051335","phase":"PHASE1","title":"Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Memory Impairment, Alzheimer's Disease","enrollment":27},{"nctId":"NCT01703260","phase":"PHASE2","title":"Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-06","conditions":"Nonalcoholic Steatohapatitis","enrollment":20},{"nctId":"NCT01664624","phase":"PHASE1","title":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT00297102","phase":"PHASE3","title":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1523},{"nctId":"NCT00313209","phase":"PHASE3","title":"Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":933},{"nctId":"NCT01329029","phase":"PHASE4","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1945},{"nctId":"NCT00424268","phase":"PHASE3","title":"Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":743},{"nctId":"NCT02187926","phase":"","title":"Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2577},{"nctId":"NCT00746434","phase":"PHASE2","title":"A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Plaque Psoriasis","enrollment":""},{"nctId":"NCT00076076","phase":"PHASE3","title":"The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-12","conditions":"Asthma","enrollment":822}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":14,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Daxas","genericName":"Daxas","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}